logo

A letter from Roche

The enrolment in the Phase III trial GENERATION HD1 study has been increased from 660 to 801 participants worldwide, as well as being extended to China.This change does not impact participants already enrolled in the study, but it allows for additional patients to enrol in the three existing study groups. By enrolling more participants, Roche […]

Read More

Update: RG6042 Phase III GENERATION HD1 study re-opens

Dear global patient community partners, Following your previous request to be kept up to date on the clinical development programme for RG6042 for Huntington’s disease, we would like to provide an update on the status of the Phase III GENERATION HD1 study (ClinicalTrials.gov ID: NCT03761849), including participating countries in Asia-Pacific, Europe, North America and South America.  […]

Read More

The inaugural conference of Huntington Disease Society of India

This picture was taken at the Inaugural conference of Huntington Disease Society of India. Among others, Svein Olaf Olsen – president of the International Huntington Association, Astri Arnesen, President of the European Huntington Association and Dr Ralf Reilmann, the founding director of the George-Huntington-Institute attended this important conference. At the conference, Neurologists and family members […]

Read More

E-health for Huntington’s patients and families

What’s is Healthe-RND?  Huntington’s disease (HD) requires intensive cooperation between different medical disciplines and services, so-called ‘multidisciplinary care’.  Given the scarcity of resources, this is not an easy task, which is why demand and reality often fall apart.  In order to be less dependent on the patients’ distance from a Huntington centre, there is an […]

Read More